Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

TABRECTA 150 MG COMPRIMIDOS RECUBIERTOS CON PELICULA - CIMA-AEMPS Drug Approval Details

Approvals/CIMA-AEMPS/TABRECTA 150 MG COMPRIMIDOS RECUBIERTOS CON PELICULA

Approved

STANDARD

TABRECTA 150 MG COMPRIMIDOS RECUBIERTOS CON PELICULA

Novartis Europharm Limited🇪🇸 Spanish Agency of Medicines and Medical Devices

Approval Date: Jul 12, 2022
Approval ID: 406e14f4a054b43a
Company: Novartis Europharm Limited
Type: Standard

Approval Details

Approval Id: 406e14f4a054b43a
Drug Cima Aemps Name: TABRECTA 150 MG COMPRIMIDOS RECUBIERTOS CON PELICULA
Register Number: 1221650002
Holder Company Name: Novartis Europharm Limited
Marketing Company Name: Novartis Farmaceutica S.A.
Holder Company Detail Path: /organization/novartis-europharm-limited
Authorization Date: 2022-07-12
Dosage Form: COMPRIMIDO RECUBIERTO CON PELÍCULA
Dose: 150 mg
Route Of Administration: VÍA ORAL
Prescription Type: Diagnóstico Hospitalario
Commercialized: Yes
Company Name: Novartis Europharm Limited
Company Detail Path: /organization/novartis-europharm-limited

Company Information

Pharmaceutical Company Name: NOVARTIS EUROPHARM LIMITED
Country Name: United Kingdom
City Name: camberley,country_gb
Address: 200 Frimley Business Park

Active Ingredients

CAPMATINIB DIHIDROCLORURO MONOHIDRATO

183 mg

Approved

Quick Info

Agency

CIMA-AEMPS

Country

🇪🇸

Approval Date

Jul 12, 2022

Approval ID

406e14f4a054b43a

Type

Standard

Back to CIMA-AEMPS Approvals